Addyi is the first and only FDA-approved treatment for HSDD, indicated for women under 65.
PRESCRIBING ADDYI JUST GOT EASIER
Addyi is the first and only FDA-approved treatment for HSDD, indicated for women under 65.
Addyi is the #1 Prescribed Treatment for HSDD.1
Did you know that nearly 3 out of 4 women are waiting for you to start the conversation about sexual health?
Keys to patient success
- Prescribe Addyi through PhilRx for the guaranteed lowest price, as little as $20 per month with commercial insurance coverage, and free home delivery (Search “PhilRx” in the EMR’s retail pharmacy finder)
- Counsel Patient to Take One 100mg Addyi Tablet Every Night at Bedtime
- If patient skips a dose, wait until the next night to resume taking Addyi.
- Addyi is dosed at bedtime because administration during waking hours increases the risks of hypotension and syncope.
- Take Addyi Once Daily For at Least 8 Weeks
- Allow at least 8 weeks for benefits to become noticeable.
- Some women may start to notice the effects of Addyi within a few weeks- an increase in sexual desire, more sexually satisfying events, and a decrease in distress. Discontinue Addyi if your patient does not see any improvements after 8 weeks.
- Consistency is key to achieving the best results.
Addyi is the #1 Prescribed Treatment for HSDD.1
Did you know that nearly 3 out of 4 women are waiting for you to start the conversation about sexual health?
Keys to patient success
- Prescribe Addyi through PhilRx for the guaranteed lowest price, as little as $20 per month with commercial insurance coverage, and free home delivery (Search “PhilRx” in the EMR’s retail pharmacy finder)
- Counsel Patient to Take One 100mg Addyi Tablet Every Night at Bedtime
- If patient skips a dose, wait until the next night to resume taking Addyi.
- Addyi is dosed at bedtime because administration during waking hours increases the risks of hypotension and syncope.
- Take Addyi Once Daily For at Least 8 Weeks
- Allow at least 8 weeks for benefits to become noticeable.
- Some women may start to notice the effects of Addyi within a few weeks- an increase in sexual desire, more sexually satisfying events, and a decrease in distress. Discontinue Addyi if your patient does not see any improvements after 8 weeks.
- Consistency is key to achieving the best results.
Addyi affects
dopamine, norepinephrine, and serotonin3
Addyi affects
dopamine, norepinephrine, and serotonin3
3. The specific mechanism of action is not fully understood.
if she’s saying these things, it may be hsdd
Learn to recognize the signs of HSDD in your patients.4
I feel stressed due to my low desire
i am no longer interested in masturbating
i don’t have sexual thoughts anymore
it’s harder for me to become aroused
i have little to no sexual desire
if she’s saying these things, it may be hsdd
Learn to recognize the signs of HSDD in your patients.4
I testified at the FDA 10 years ago when Addyi was approved — a watershed moment that validated women’s sexual health with the first FDA approved option to treat women with frustrating low libido. In my practice, it opened conversations that had long been silenced and gave patients hope.
Dr. Alyse Kelly-Jones, Ob/Gyn
I testified at the FDA 10 years ago when Addyi was approved — a watershed moment that validated women’s sexual health with the first FDA approved option to treat women with frustrating low libido. In my practice, it opened conversations that had long been silenced and gave patients hope.
Dr. Alyse Kelly-Jones, Ob/Gyn
IN THEIR WORDS
real experiences. real reviews.
IN THEIR WORDS
real experiences. real reviews.
“Addyi has helped me get my libido back. My sweet husband has been so patient with me for years now – I dreaded his advances – I can’t tell you how wonderful it has been to want sex again.”
Elizabeth, 45, Addyi patient
“When I heard about Addyi, I was curious if it would work for me. After only a few weeks on Addyi I’m already thinking about and wanting sex again!”
Caroline, 60, Addyi patient
“I used to dread going to bed with my husband, because I was never in the mood… he thought it was his fault. We were really struggling. Then we found Addyi!”
Kendall, 31, Addyi patient
34,000+
Prescribers
34,000+
Prescribers
As Seen In
Contact Us
MEDICAL INFO:
844-746-5745 x 4
medicalaffairs@sproutpharma.com
Contact Us
MEDICAL INFO:
844-746-5745 x 4
medicalaffairs@sproutpharma.com
- IQVIA Monthly Total Prescriptions Volume Data Comparing Addyi vs Vyleesi in the US. April 2024–April 2026
- Ryan KL, Arbuckle-Bernstein V, Smith G, Phillips J. Let’s Talk About Sex: A Survey of Patients’ Preferences When Addressing Sexual Health Concerns in a Family Medicine Residency Program Office. PRiMER. 2018;2:23. https://doi.org/10.22454/PRiMER.2018.728252
- Stahl SM, et al. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011;8:15-27
- Www.medicalnewstoday.com, 30 Nov. 2022, www.medicalnewstoday.com/articles/hypoactive-sexual-desire-disorder#overview
- Gerstenberger EP, Rosen RC, Brewer JV, et al. Sexual desire and the Female Sexual Function Index (FSFI): a sexual desire cutpoint for clinical interpretation of the FSFI in women with and without hypoactive sexual desire disorder. J Sex Med. 2010;7(9):3096–3103.
- Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2006; 26:2, 191-208.
- Addyi Prescribing Information.
- https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
- Clayton AH, Harry AC, Yuan J, et al. Safety of flibanserin in women treated with antidepressants: A randomized, placebo-controlled study. J Sex Med 2018;15(1):43-51.
- Arnow BA, Millheiser L, Garrett A et al. Women with hypoactive sexual desire disorder compared to normal females: a functional magnetic resonance imaging study. Neuroscience 2009;158:484-502.
- Woodard TL, Nowak NT, Balon R et al. Brain activation patterns in women with acquired hypoactive sexual desire disorder and women with normal sexual function: a cross-sectional pilot study. Fertil Steril 2013;100:1068-1076.
- Bianchi-Demicheli F, Cojan Y, Waber L, et al. Neural basis of hypoactive sexual desire disorder in women: an event-related fmri study. J Sex Med. 2011;8:2546-2559.
- Holstege G. How the emotional motor system controls the pelvic organs. Sex Med Rev. 2016: 4;303-328.
- Kingsberg SA. Attitudinal survey of women living with low sexual desire. J Women’s Health. 2014;23(10):817-23
- Clayton AH, Brown L, Kim NN. Evaluation of safety for flibanserin. Expert Opin Drug Saf. 2020;19(1):1-8. doi:10.1080/14740338.2020.1707804
- Goldfischer ER, Breaux J, Katz M et al. Continued efficacy and safety of flibanserin in premenopausal women with hypoactive sexual desire disorder (HSDD): Results from a randomized withdrawal trial. J Sex Med.2011; 8:3160-3172.
- Jayne C, Simon JA, Taylor LV, Kimura T, Lesko LM; SUNFLOWER study investigators. Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med. 2012;9(12):3180-3188. doi:10.1111/j.1743-6109.2012.02942.x
- Kornstein SG, James JA, Apfel SC, et al. Effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with hypoactive sexual desire disorder: A post hoc analysis. J Women’s Health. 2017;26(11):1161-1168.
IMPORTANT SAFETY INFORMATION
WARNING: RISK OF HYPOTENSION AND SYNCOPE IN CERTAIN SETTINGS
See full prescribing information for complete boxed warning.
- Use of ADDYI and alcohol together close in time increases this risk. Counsel patients to wait at least two hours after consuming one or two standard alcoholic drinks before taking ADDYI at bedtime or to skip their ADDYI dose if they have consumed three or more standard alcoholic drinks that evening.
- Use of ADDYI is contraindicated with strong or moderate CYP3A4 inhibitors orin patients with hepatic impairment.
Contraindications
- Moderate or strong CYP3A4 inhibitors
- Hepatic impairment
- Known hypersensitivity to ADDYI or any of its components. Reactions,including anaphylaxis, angioedema, pruritus, and urticaria have been reported.
Warnings and Precautions
- Hypotension and Syncope Due to Alcohol Interaction: See Boxed Warning.
- Hypotension and Syncope with CYP3A4 Inhibitors: See Boxed Warning and Contraindications. Concomitant use of multiple weak CYP3A4 inhibitors that may include herbal supplements (e.g., ginkgo, resveratrol) or non-prescription drugs (e.g., cimetidine) may also increase the risk.
- Central Nervous System (CNS) Depression: The risk is increased if ADDYI is taken during waking hours; with alcohol; with other CNS depressants; or with CYP3A4 inhibitors.Patients should avoid activities requiring full alertness(e.g., driving or operating machinery) until at least 6 hours after taking ADDYI and until they know how it affects them
- Hypotension and Syncope with ADDYI Alone: The risk is increased if ADDYI is taken during waking hours or if higher than the recommend dose is taken.
- Syncope and Hypotension in Patients with Hepatic Impairment: See Contraindications.
- Hypersensitivity Reactions: See Contraindications. Immediately discontinue ADDYI and initiate appropriate treatment if hypersensitivity reaction occurs.
Drug Interactions
- Oral Contraceptives and Other Weak CYP3A4 Inhibitors: Increases flibanserin exposures and incidence of adverse reactions.
- Strong CYP2C19 Inhibitors: Increases flibanserin exposure which may increase risk of hypotension, syncope, and CNS depression.
- Digoxin: Increases digoxin concentrations, which may lead to digoxin toxicity. Increase monitoring of digoxin concentrations.
Most Common Adverse Reactions
- Most common adverse reactions (≥2% and higher than placebo) are dizziness, somnolence, nausea, fatigue, insomnia, urinary tract infection, anxiety, sinusitis, constipation and dry mouth
Please see accompanying full Prescribing Information including BOXED WARNING at ADDYI.com/PI
INDICATION
ADDYI is indicated for the treatment of women<65 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD),characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to: aco-existing medical or psychiatric condition; problems within the relationship; or the effects of a medication or other drug substance.
Limitations of Use:ADDYI is not for use in men or to enhance sexual performance.